According to its SEC 13F filed on Nov 16, 2026, Tang Capital Management reported 42 long positions worth $2.16B as of Sep 30, 2026. AUPH is 9.7% of the portfolio and the top 10 holdings are 64%. Against Q2 2026 it opened 5 new positions, added to 11, trimmed 0 and exited 1. 7 holdings have a dated FDA decision or data readout in the next 90 days, and 11 more expect one in a stated window such as "H2 2026".
Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval
5 more with a subscription
Full lists with a subscription
13F value by quarter, Q1 2021 to Q3 2026
By company stage (share of value)
Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.
| Stock | Company Name | Shares Held | Market Value | % of Portfolio | QoQ Change | Position Change | Also Held By | Stage | Next Catalyst |
|---|---|---|---|---|---|---|---|---|---|
MRNA | MODERNA INC | 50.00 K | 9.63 M | 0.4 | Unchanged | Commercial | Dec 12, 2026 Phase 1/2 data presentation | ||
VRDN | VIRIDIAN THERAPEUTICS INC | 1.79 M | 36.91 M | 1.7 | Unchanged | Commercial | Expected Q4 2026 IND Submission | ||
LKFT | LAKEFRONT BIOTHERAPEUTICS NV | 3.99 M | 118.18 M | 5.4 | New | Clinical | Dec 13, 2026 Phase 1b data presentation | ||
KNSA | KINIKSA PHARMACEUTICALS INTL | 2.26 M | 168.61 M | 7.8 | Unchanged | Commercial | None in 90 days | ||
TARS | TARSUS PHARMACEUTICALS INC | 1.92 M | 150.75 M | 6.9 | Added +22% | Commercial | None in 90 days | ||
NVCT | NUVECTIS PHARMA INC | 1.58 M | 33.33 M | 1.5 | Added +2% | Clinical | Expected Q4 2026 IND Submission |
Size = share of the portfolio. Option positions show CALL or PUT.
All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.
42 stocks worth $2.16B at Sep 30, 2026, as reported in its 13F, led by AUPH (9.7% of the portfolio). The full list is in the Holdings table above.
Against Q2 2026: 5 new positions, 11 increases, 0 reductions and 1 full exits, from its 13F filings.
13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q4 2026) is due Feb 16, 2027.
Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.
Source: SEC EDGAR Form 13F-HR filed by TANG CAPITAL MANAGEMENT LLC, accession 0001214659-26-014410, filed Nov 16, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.